CD40 immunotherapy for pancreatic cancer

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

(2013) Robert H. Vonderheide et al.   OncoImmunology

Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer

(2012) Lauren J. Bayne et al.   CANCER CELL

Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia

(2012) Yuliya Pylayeva-Gupta et al.   CANCER CELL

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

(2012) Timothy O’Sullivan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

(2011) Jens Rüter et al.   CANCER BIOLOGY & THERAPY

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

(2011) Ronald P. Gladue et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

(2010) Alberto Mantovani et al.   CURRENT OPINION IN IMMUNOLOGY

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein- 

(2010) M. Kraman et al.   SCIENCE

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

(2009) Erica L Carpenter et al.   Journal of Translational Medicine

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines

(2008) C. L. Ahonen et al.   BLOOD

CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors

(2008) Alexander L. Rakhmilevich et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer

(2008) Carolyn E. Clark et al.   CANCER LETTERS